Featured Research

from universities, journals, and other organizations

Directly Observed HIV Therapy For Children Is Promising

Date:
June 4, 2007
Source:
Brown University
Summary:
The first study in the developing world of directly observed antiretroviral therapy for HIV-infected children shows this form of treatment is an inexpensive, effective way to ensure that children take life-saving medications. Without antiretroviral treatment, half of all HIV-infected children die by age 2. With therapy, however, many children survive to adulthood.

Dr. David Pugatch and colleagues have shown that directly observed therapy increases adherence to treatment regimens, improves outcomes, and reduces the risk of drug resistance among HIV-infected children in developing countries.
Credit: David Pugatch

Directly observed antiretroviral therapy is a promising strategy to ensure that HIV-infected children in developing countries take life-saving medications, new research from The Warren Alpert Medical School of Brown University shows. The study was conducted in collaboration with Maryknoll, the international Catholic charity that runs a program for AIDS orphans in Phnom Penh, Cambodia’s capital city. The study is the first to test the benefits of directly observed treatment in children living in developing countries.

“Results of this study tell us that directly observed treatment for children with HIV is an important strategy to consider in resource-limited settings” said David Pugatch, M.D., director of the pediatric and adolescent HIV program at Hasbro Children’s Hospital and an assistant professor of pediatrics at The Alpert Medical School.

“With the cost of AIDS drugs dropping, antiretroviral treatments are increasingly becoming available in Asia, Africa and Latin America,” Pugatch said, “yet there is little evidence of what is the best way to deliver these drugs to children living in these countries. We found that directly observed therapy is an effective and economical way to go.”

Without antiretroviral treatment, half of all HIV-infected children die by age 2. With therapy, however, many children survive to adulthood. That’s why the World Health Organization is calling for worldwide universal access to antiretroviral therapy by 2010.

But what’s the best way to deliver these drugs to children in developing countries, places with often limited access to basic tests and trained professionals? Pugatch and his Brown colleagues, who have helped combat AIDS in Cambodia for years, decided to find out.

They evaluated the outcomes of HIV-infected children receiving directly observed therapy, a method that calls for health care workers to either watch patients take every drug dose or deliver those doses themselves. This method, widely used to combat tuberculosis, is aimed at ensuring that people take their medications. That adherence will keep patients healthy and reduce the likelihood of drug resistance.

Researchers evaluated HIV-infected children living in orphanages or with extended family in Phnom Penh. Researchers assessed 117 late-stage HIV-infected children ages 1 to 13.

Because treatment started so late, 22 children died of AIDS within the first six months. The remaining 95 children were treated for at least six months or as many as 18 months. Trained childcare workers administered the generic drugs, in liquid or pill form, twice daily.

The results

The number of immunity-boosting T helper cells in the blood of children more than tripled. Children gained significant amounts of weight. Drug toxicities were uncommon and easily managed. And the price was right: Staff costs for the program were about $5 per child per month, or 15 percent0 more than the price of the medications. Calculated another way, it cost $400 per child per year to buy the drugs and another $60 to pay the professionals who administered them.

“For just a little extra money, we could be sure that children had 100 percent adherence to their medications,” Pugatch said. “We know that a high degree of adherence reduces the chances of drug resistance – which can lead to treatment failure and the need to put kids on more expensive, second-line therapies.”

The next steps researchers must take, Pugatch said, are to conduct a randomized, controlled trial to compare directly observed therapy with standard care as well as to conduct a rigorous cost-benefit analysis. “We need to know what works in treating children in resource-poor settings so we know where to put limited HIV treatment dollars,” he said.

Patricia Myung, M.D., a former Brown medical student and current resident at the University of California–Irvine, is lead author of the article. Brown medical student Mark Brady was part of the research team, along with Mark Lurie, assistant professor of community health, and Joseph Harwell, M.D., assistant professor of medicine and pediatrics and attending physician at The Miriam Hospital. Former Maryknoll program directors Phok Many and John Tucker also conducted the research.

Findings are published in the June issue of the American Journal of Public Health.


Story Source:

The above story is based on materials provided by Brown University. Note: Materials may be edited for content and length.


Cite This Page:

Brown University. "Directly Observed HIV Therapy For Children Is Promising." ScienceDaily. ScienceDaily, 4 June 2007. <www.sciencedaily.com/releases/2007/06/070601101123.htm>.
Brown University. (2007, June 4). Directly Observed HIV Therapy For Children Is Promising. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2007/06/070601101123.htm
Brown University. "Directly Observed HIV Therapy For Children Is Promising." ScienceDaily. www.sciencedaily.com/releases/2007/06/070601101123.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins